Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease ; volume:12 ; number:1 ; day:28 ; month:6 ; year:2024 ; pages:1-4 ; date:12.2024
Acta Neuropathologica Communications ; 12, Heft 1 (28.6.2024), 1-4, 12.2024
- Creator
-
Henderson, Michael X.
Sengupta, Medha
Trojanowski, John Q.
Lee, Virginia M. Y.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-024-01819-7
- URN
-
urn:nbn:de:101:1-2410080927235.638132601369
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Henderson, Michael X.
- Sengupta, Medha
- Trojanowski, John Q.
- Lee, Virginia M. Y.
- SpringerLink (Online service)
Other Objects (12)
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Towards enabling precision medicine in Alzheimer's disease and Parkinson's disease
LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Towards enabling precision medicine in Alzheimer's disease and Parkinson's disease
LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Towards enabling precision medicine in Alzheimer's disease and Parkinson's disease